Generic Approved for Ery-Tab
July 2, 2019 – The U.S. FDA has approved the first generic for Arbor Pharmaceuticals’ Ery-Tab® (erythromycin delayed release tablets). The generic, manufactured Amneal Pharmaceuticals, is available in 250mg, 333mg, and 500mg dosage strengths.
Erythromycin delayed-release tablets are an antibiotic indicated to treat certain eye, respiratory, skin, urinary, and sexually transmitted infections. Recommended dosing for adults ranges from 250mg to 500mg taken on an empty stomach up to four times a day, based on individual patient factors. Pediatric dosing is based the patient’s age and weight, and the severity of infection. Patients of any age should take no more than 4g in a 24-hour period. Treatment can last from one to four weeks based on severity of infection.
Amneal’s generic is interchangeable only with Ery-Tabs, although other forms and brands of erythromycin are available on the market. The product has launched at an average wholesale price (AWP) of $316.86 per 30-count of 333mg tablets, compared to $333.54 for the brand.